Close
Achema middle east
swop processing & packaging

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sharp invests $20 million in autoinjector & pen assembly lines to meet rising demand for injectables

Sharp Services, a leader in pharmaceutical packaging, clinical trial...

CPHI Frankfurt Pharma Awards 2025 Finalists Announced

Hundreds of entries received across 14 categories showcasing innovation,...

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Haelon CEO

Haleon today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025.

This appointment follows Franck Riot deciding to leave Haleon after six years in the business.

Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care.

Brian McNamara, Haleon’s Chief Executive Officer commented:

“I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experience of driving transformative innovation within global consumer businesses. He will be an excellent addition to our executive team as we look to build on the strong foundations we have built in recent years and unlock Haleon’s significant potential through our new Win as One strategy.

“I want to take this opportunity to thank Franck for his significant contribution to Haleon over the last six years. He has played an important role in the lead up to and beyond separation to move our innovation agenda forward and prepare us for the next phase of our journey. On behalf of everyone at Haleon, I wish him the very best for the future.”

Carl Haney commented:

“I am hugely excited to be joining Haleon at such an important stage of its journey, as it looks to capitalise on the significant opportunities ahead and continues its transformation into a world class consumer company. I am incredibly passionate about the role that R&D can play in delivering Haleon’s ambitions and its purpose of delivering better everyday health with humanity. I am very much looking forward to meeting the team and getting started in August.”

Latest stories

Related stories

Sharp invests $20 million in autoinjector & pen assembly lines to meet rising demand for injectables

Sharp Services, a leader in pharmaceutical packaging, clinical trial...

CPHI Frankfurt Pharma Awards 2025 Finalists Announced

Hundreds of entries received across 14 categories showcasing innovation,...

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »